Posts

Friday Five: Freenome's CRC Test Wins FDA Nod

on

Bristol lays out KRAS med Krazati's stumble in confirmatory colorectal cancer trial

on

Bristol Myers details Krazati confirmatory study failure in colorectal cancer

on

Exelixis' TKI falls short in colorectal cancer subgroup as FDA reviews approval in all-comers

on

First Patient Dosed in Phase 1b/2 Trial of HLX701 Combination Therapy for Advanced Colorectal Cancer

on

Astellas Ends Partnership with CytomX Despite Positive Phase 1 Data for Probody Platform

on

CytomX Announces Positive Phase 1 Data for Varsetatug Masetecan in Late-Line Colorectal Cancer

on

Oncoinvent ASA Announces Second Half 2025 Results with Positive Radspherin Trial Data and Corporate Milestones

on

Oncolytics Biotech Expands GI Tumor Scientific Advisory Board with Eileen O’Reilly, Neil Segal, and Van Morris

on

Exelixis' Kinase Blocker Zanzalintinib Sets New Survival Standard in Third-Line Metastatic Colorectal Cancer, Paving Way for FDA Review

on

Roche Inks $80M Upfront Deal for Hansoh's Cancer ADC HS-20110

on

Lunit AI Predicts Immunotherapy Outcomes in Colorectal, Kidney, and Lung Cancer at ESMO 2025

on

Cartography Biosciences Closes $67 Million Series B Round Led by Pfizer to Advance CRC T-cell Engager

on

CytomX Continues Phase I ADC Study After Patient Death

on

Exelixis' Zanzalintinib Achieves Key Survival Goal in Pivotal Colorectal Cancer Study

on

Exelixis' Phase 3 Colorectal Cancer Data Sends Stock Higher

on

AACR 2025 Tracker: Marengo, BriaCell, Present Promising Data

on

: BMS' Opdivo plus Yervoy snags FDA nod as first-line treatment for certain colorectal cancer patients

on